Compare iShares MSCI China ETF (MCHI) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI China ETF vs Medpace Holdings Inc — how do they compare? iShares MSCI China ETF trades at $54.09, while Medpace Holdings Inc trades at $534.03 (market cap $15.08B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, iShares MSCI China ETF nearer its low. Which is the better fit depends on your goals.
| MCHI | MEDP | |
|---|---|---|
Sector | Broad Market / Factor | Technology |
52-Week High | $66.99 | $620.59 |
52-Week Low | $50.48 | $308.88 |
Market Cap | — | $15.08B |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MCHI trades at $54.08, up 2.13% today, but technical indicators signal a bearish trend with moving averages showing sell pressure. The stock lacks key valuation metrics like P/E and P/S, and recent news highlights China's economic stimulus focus and AI sector growth, which could impact this China-focused ETF. Dividend activity is scheduled for mid-2026.
The outlook is cautious due to bearish technicals and macroeconomic risks from U.S.-China tensions, though AI-driven exports offer growth potential. Investors face value trap risks amid mixed analyst sentiment, requiring close monitoring of China's policy developments and corporate earnings for directional cues.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI China ETF
MCHI is an ETF that seeks to track the investment results of the MSCI China Index. It provides broad exposure to the Chinese equity market, primarily focusing on large and mid-cap companies listed in Hong Kong and Shanghai. MCHI serves as a core holding for investors looking to gain diversified exposure to the performance and growth potential of the companies within the People's Republic of China.
Read more on MCHI →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
